Literature DB >> 16904643

The N-terminal domain of CCL21 reconstitutes high affinity binding, G protein activation, and chemotactic activity, to the C-terminal domain of CCL19.

Thomas R Ott1, Francisco M Lio, Dennis Olshefski, Xin-Jun Liu, Nicholas Ling, R Scott Struthers.   

Abstract

CC chemokine receptor 7 (CCR7), which regulates the trafficking of leucocytes to the secondary lymphoid organs, has two endogenous chemokine ligands: CCL19 and CCL21. Although both ligands possess similar affinities for the receptor and similar abilities to promote G protein activation and chemotaxis, they share only 25% sequence identity. Here, we show that substituting N-terminal six amino acids of CCL21 (SDGGAQ) for the corresponding N-terminal domain of CCL19 (GTNDAE) results in a chimeric chemokine that exhibits high affinity binding and G protein activation of CCR7. These data demonstrate that despite dissimilar sequences, the amino terminal hexapeptide of these two chemokines is capable of performing similar roles resulting in receptor activation.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16904643     DOI: 10.1016/j.bbrc.2006.07.165

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  8 in total

1.  Dendritic cell chemotaxis in 3D under defined chemokine gradients reveals differential response to ligands CCL21 and CCL19.

Authors:  Ulrike Haessler; Marco Pisano; Mingming Wu; Melody A Swartz
Journal:  Proc Natl Acad Sci U S A       Date:  2011-03-21       Impact factor: 11.205

2.  Lymphoidal chemokine CCL19 promoted the heterogeneity of the breast tumor cell motility within a 3D microenvironment revealed by a Lévy distribution analysis.

Authors:  Beum Jun Kim; Pimkhuan Hannanta-Anan; Anders Ryd; Melody A Swartz; Mingming Wu
Journal:  Integr Biol (Camb)       Date:  2020-02-22       Impact factor: 2.192

3.  Selective engagement of G protein coupled receptor kinases (GRKs) encodes distinct functions of biased ligands.

Authors:  David A Zidar; Jonathan D Violin; Erin J Whalen; Robert J Lefkowitz
Journal:  Proc Natl Acad Sci U S A       Date:  2009-06-02       Impact factor: 11.205

4.  Combinatorial guidance by CCR7 ligands for T lymphocytes migration in co-existing chemokine fields.

Authors:  Saravanan Nandagopal; Dan Wu; Francis Lin
Journal:  PLoS One       Date:  2011-03-25       Impact factor: 3.240

5.  Selective Boosting of CCR7-Acting Chemokines; Short Peptides Boost Chemokines with Short Basic Tails, Longer Peptides Boost Chemokines with Long Basic Tails.

Authors:  Emma Probst Brandum; Astrid Sissel Jørgensen; Marina Barrio Calvo; Katja Spiess; Francis C Peterson; Zhang Yang; Brian F Volkman; Christopher T Veldkamp; Mette Marie Rosenkilde; Christoffer Knak Goth; Gertrud Malene Hjortø
Journal:  Int J Mol Sci       Date:  2022-01-26       Impact factor: 5.923

6.  The C-terminal peptide of CCL21 drastically augments CCL21 activity through the dendritic cell lymph node homing receptor CCR7 by interaction with the receptor N-terminus.

Authors:  Astrid Sissel Jørgensen; Emma Probst Brandum; Jeppe Malthe Mikkelsen; Klaudia A Orfin; Ditte Rahbæk Boilesen; Kristoffer Lihme Egerod; Natasha A Moussouras; Frederik Vilhardt; Pawel Kalinski; Per Basse; Yen-Hsi Chen; Zhang Yang; Michael B Dwinell; Brian F Volkman; Christopher T Veldkamp; Peter Johannes Holst; Katharina Lahl; Christoffer Knak Goth; Mette Marie Rosenkilde; Gertrud Malene Hjortø
Journal:  Cell Mol Life Sci       Date:  2021-09-29       Impact factor: 9.207

7.  Convolution of chemoattractant secretion rate, source density, and receptor desensitization direct diverse migration patterns in leukocytes.

Authors:  Yana Wang; Darrell J Irvine
Journal:  Integr Biol (Camb)       Date:  2013-03       Impact factor: 2.192

8.  Lactobacillus plantarum displaying CCL3 chemokine in fusion with HIV-1 Gag derived antigen causes increased recruitment of T cells.

Authors:  Katarzyna Kuczkowska; Geir Mathiesen; Vincent G H Eijsink; Inger Øynebråten
Journal:  Microb Cell Fact       Date:  2015-10-22       Impact factor: 5.328

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.